CSIR signs deal on rabies research

2012-07-16 14:42
The CSIR has entered into a partnership that should the see the research organisation being granted access to a manufacturing platform for rabies medication. (AP)

The CSIR has entered into a partnership that should the see the research organisation being granted access to a manufacturing platform for rabies medication. (AP)

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories


VIDEO: Rabies symptoms

2012-07-16 14:37

Peter Costa explains the symptoms of rabies in this YouTube video.WATCH

Cape Town - The Council for Scientific and Industrial Research (CSIR) has entered into a partnership that should the see the research organisation being granted access to a plant-based manufacturing platform for rabies medication.

The CSIR concluded an agreement with Icon Genetics, subsidiary of Nomad Bioscience GmbH in Munich, to conduct royalty-free manufacturing of the rabies vaccine and post-exposure prophylaxis antibodies against rabies for the Sub-Saharan Africa region.

"Under the recently signed agreement, Icon will provide the materials, know-how, training, R&D [research and development] licence, as well as royalty free commercial licence option to the CSIR," the CSIR told News24.

The manufacturing technology known as magnICON allows for fast and high-level expression of recombinant proteins, in particular pharmaceuticals, in green plants.

"The speed, efficiency and yield of recombinant protein from plants provided by magnICON is the highest in the industry based on Frost & Sullivan's independent analysis of recombinant expression systems," said the CSIR.


The partnership could potentially reduce the cost and accessibility challenges related to rabies medication. The disease affects the nervous system and the period between infection and the fist first flu-like symptoms is between two to 12 weeks.

The virus typically causes inflammation of the brain and though the infection is easily treatable, it is usually fatal once it reaches the central nervous system.

"Biopharming represents a unique opportunity for countries like South Africa to participate in the local production of high value biotechnology drugs and reagents for human and animal health," said Dr Rachel Chikwamba, the CSIR's group executive of Strategic Alliances and Communication.

Over 95% of rabies infections result from dog bites and despite the disease being eliminated in developed countries like Japan and the UK, it remains a problem in Africa, with 48 countries in need of medicines to control the disease.

It is estimated that around 55 000 people die annually from rabies, most of those in developing countries in Africa and Asia. In SA, between 10 to 30 cases of rabies are confirmed every year.

This partnership is the second major one signed between SA and an international company this year as part of the government's drive to reduce the cost of medicines.


The South African government recently created a joint venture with Swiss firm Lonza to produce active pharmaceutical ingredients (APIs) for anti-retroviral medicines in SA.

South Africa imports over R25bn worth of drugs annually and it is estimated that local manufacture of the API will greatly reduce the cost of HIV, tuberculosis and malaria medications.

"We admire efforts at the CSIR to develop the new medicines for underprivileged parts of the world's population," said Dr Victor Klimyuk, Icon's chief operations officer.

- Follow Duncan on Twitter
Read more on:    health  |  research

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

linking and moving

2015-04-22 07:36

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.